VolitionRx is a life sciences company developing novel, simple-to-use, blood-based tests to diagnose a broad range of cancers and other conditions, by identifying and measuring nucleosomes in the bloodstream. The tests are based on the science of Nucleosomics™, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid – an indication that disease is present. Volition is primarily focused on human diagnostics, but also has a subsidiary focused on animal diagnostics.
In this video, VolitionRx’s president and chief executive officer Cameron Reynolds discusses the company’s third quarter financial results and operational progress. In addition, he discusses the company’s first product launch, the Nu.Q™ Vet Cancer Screening Test, which will launch on 30 November. During the quarter, Volition made considerable progress in its human cancer programme and, in particular, in blood cancer where it successfully obtained similar results in both humans and dogs using the same assay. In terms of financials, cash and cash equivalents as at 30 September 2020 totalled approximately $21m compared with $17m as at 31 December 2019.